pro.oxfordclub.com Open in urlscan Pro
192.135.136.168  Public Scan

Form analysis
1 forms found in the DOM

POST

<form action="" id="EmailCapture" method="post"><input class="mvcode" name="MultivariateId" type="hidden" value=""> <input name="NotSaveSignup" placeholder="email" type="hidden" value="False"> <input class="coreg" name="CoRegs" type="hidden"
    value="">
  <div class="form-group"><input class="email form-control" id="email" name="email" placeholder="Enter Your Email" required="" type="text" value=""></div>
  <!--  you can add passthrough class to completely override leadgen for this form
				  	if leadgen is elsewhere on the page-->
  <div class="center"><input class="leadSubmit btn btn-primary EmailSubmit" data-portrait-position="clickpop-orderform-button" data-portrait-type="order-form-link" name="submit" style="white-space: normal;" type="button"
      value="Continue to Secure Registration Page"></div>
</form>

Text Content

A MARC LICHTENFELD EXCLUSIVE EVENT


WHY NVIDIA IS GOING ALL-IN ON THIS $10 TECHBIO STOCK


AND WHY YOU SHOULD GET IN BEFORE SEPTEMBER 1 AHEAD OF A MAJOR ANNOUNCEMENT THAT
COULD SEND SHARES SOARING

Click for sound










JOIN NOW
Read the Transcript
George:

Hi, I'm George Rayburn.

Today I'm joined by America’s #1 stock catalyst expert Marc Lichtenfeld.

His insights have been featured on Fox Business, CNBC, Bloomberg, MarketWatch
and Yahoo Finance and in The Wall Street Journal, Forbes and more.

According to Marc, the greatest AI stock story EVER is happening right now. He
says it could change the course of human health… forever.

And he’s not alone.

Jensen Huang, the Chief Executive Officer of Nvidia says this will be “…the next
amazing revolution... It will be one of the biggest ever.”

But listen, these are more than just words from Nvidia’s CEO.

In fact, it’s about cold hard cash.

Nvidia just did something very unusual.

They made a MASSIVE investment directly in one small biotech firm that trades
for less than $10.

Why?

It’s just ahead of a major announcement that could send shockwaves through the
market.

Nvidia is setting themselves up for a major windfall.

And my guest, Marc Lichtenfeld, is sending out an alert now so that regular
investors can join in on the big moment.

It’s all set to kick off as soon as September 1… when this tiny firm will make
that huge announcement.

Marc says this breakthrough will ignite a revolution in AI biotech... and could
make early investors a fortune.

Keep in mind, Marc has a proven track record across various services of
uncovering great companies on the verge of experiencing trigger events – much
like this one.

He identified Synergy Pharmaceuticals 9 days before a big trigger event... and
it exploded 84% in a single day. The stock, not the options. His official
tracked gain was 62%

He also recommended Celldex Therapeutics which returned 419% in less than a
year. Again, we’re talking about the stock, quintupling in 10 and a half months.

Then there was his trade in NPS Pharmaceuticals which resulted in a total return
of 550% in 4 ½ months.

And not long ago, he made a bold guarantee on another biotech company – saying
he expected a trade on it would soar 519% in a year.

He got a ton of backlash.

Internet trolls laughed at him... saying – and I quote – Marc’s prediction
“smelled like pig feces.”

To be fair, Marc’s prediction wasn’t entirely accurate.

He didn’t deliver a 519% gain in one year...

His official trade closed for – get this – 907% in under a year.

Carl Marshall, one of Marc’s followers, said he made almost $100,000.

Another, Anthony Valentino, wrote in to say he and his brother made a stunning
$1.3 million on just that one trade!

Those are just a few extraordinary examples.

And they each experienced trigger events ahead of their big jumps in price...
but nowhere near as impactful as the coming catalyst for Nvidia’s favorite
biotech company.

Because there is one key difference that could make this Marc’s biggest and best
prediction to date.

You should know, he has spent over 25 years studying this lucrative corner of
the market.

He’s a regular attendee at the invitation-only JP Morgan Healthcare conference.

He’s helped everyday people like Ben H. turn $775 into $10,500 in 6 months…

Bart B. increase his portfolio by 300% in just 12 months…

And he helped Colin J. make a 126% return in 46 days… resulting in a $200,000
payday.

Marc has traveled the world to biotech hotbeds from San Francisco to
Jerusalem...

All so he could personally hear important developments directly from CEOs and
executives.

So please pay close attention. Because I cannot stress enough the urgency here.

This situation is expected to unfold as early as September 1... As you’ll see,
opportunities like this don’t come along often.

Welcome, Marc. Thanks for being here.

Marc:

My pleasure. Thank you for having me.

George:

Now, I know that time is very much of the essence. So, if you don’t mind, I just
want to jump right into it.

Marc, we were talking a bit earlier. To say you’re excited about this company
would be a gross understatement.

And our audience wants to know what’s going on!

So, please, tell us how an announcement from this company – one that practically
no one has heard of – could turn a small stake into a fortune and thrust the
entire AI biotech revolution into overdrive.

Marc:

OK, so first of all... you’re absolutely correct. I am beyond excited about this
company.

I foresee huge gains immediately following this upcoming announcement, which
could hit as early as September 1.

BUT it’s not entirely true that no one has heard of this stock.

I mean, it's not a company on the average investor’s radar. Not yet.

But industry leaders like Roche-Genentech and Bayer have already teamed up with
it.

Baillie Gifford & Co., a money manager famous for being an early investor in
stocks like Tesla and Moderna is this firm’s largest holder.

And here’s the real game changer…

The most powerful player in all of AI is betting big on this small company.

George:

You’re talking about Nvidia.

Marc:

That’s right.

George:

I’ve got a ton of questions. But before we can even get into all of that…

I have to ask…

Nvidia is a $2.5 trillion-dollar AI powerhouse.

So why is it investing heavily in biotechnology of all things?

That seems very unusual to be entering an entirely different field like it is.

What’s Nvidia’s plan here?

Marc:

GEORGE, this move perfectly aligns with Nvidia's broader strategy of expanding
beyond its core chip business...

The AI giant is positioning itself not only a provider, but THE provider of
essential computing infrastructure and services across the entire AI landscape.

So In short, Nvidia wants to be the single greatest AI company in the world.

And so, they’re investing directly in what they consider to be the biggest
innovations in artificial intelligence.

Jensen Huang, Nvidia’s CEO, has repeatedly said that digital biology will be one
of the biggest technological revolutions EVER… And… well…

He’s putting his money where his mouth is.

Because this small firm is set to announce a new biotech use for AI that I
believe will fundamentally reshape humanity forever.

George:

...So of COURSE the undisputed AI champion, Nvidia, wants to lead the charge on
this biotech revolution.

Marc:

Exactly.

And to be clear, this $10 stock isn’t any old biotech.

Out of the more than 6,600 biotech companies that operate in the United States,
this is the ONE – the only one – that Nvidia is investing in on a major scale.

To give you an idea, Nvidia’s portfolio is comprised of 5 stocks… and 97% of
that portfolio is invested in just two holdings.

This tiny firm being one of them.

There’s a reason I call it Nvidia’s favorite biotech.

George:

Well, that’s certainly quite a vote of confidence.

Certainly, Nvidia must recognize something in this company that has them
excited.

Marc:

Oh for sure.

Kimberly Powell, Nvidia’s VP of healthcare recently said, “The computer-aided
design industry created the first $2 trillion chip company. Why wouldn't the
same computer aided drug discovery industry build the next trillion-dollar drug
company?”

And then she added this… which is the most telling part…

She said, “Which is why we are investing in it the way that we are.”

George:

Wait a minute… let me just back up for a second.

Basically, a top executive at Nvidia is telling us they expect AI to create a
trillion-dollar drug company… so they are investing ahead of that.

And we know exactly WHERE they’re investing… It’s in this $10 stock.

Let me ask you this Marc…

If that comes true – if Nvidia’s favorite biotech becomes a $1 trillion market
leader, how big of a gain will that be from here?

Marc:

It’s massive, George.

Currently, the market cap of this company is about $2 billion.

It would have to increase nearly 500 times in value to hit a $1 trillion.

Again, this is why I am so excited about this opportunity.

And why I think it is crucial people act before the major announcement they have
planned.

I’m expecting it as early as September 1.

And it could set the market on fire when it happens.

George:

That’s incredible.

So, then let me ask you...

Why was this the one out of 6,600 biotechs that Nvidia just HAD to partner with
on a major scale?

Why is THIS the one that they suggested could be the next trillion-dollar drug
company?

Marc:

In a nutshell, this company has developed a groundbreaking AI-driven platform
for drug development and discovery.

It’s as revolutionary as when making cars went from being custom-made by hand to
the assembly line. Maybe even more so…

Using AI, this small company can execute up to 2.2 million experiments per week.

Dr. Juergen Eckhardt is the head of business development at Bayer – another
major player that has teamed up with Nvidia’s favorite biotech. And he confirms
that, “The methodology in which [this company] uses artificial intelligence in
drug discovery could be one of the most disruptive technologies of our time.”

George:

Most disruptive technologies of our time! That’s huge!

Marc:

It sure is.

He believes it.

I believe it.

And it’s clear that Nvidia believes it, too.

But let me explain exactly what’s going on here.

This company has THE fastest and most powerful computer in all of pharma.

And thanks to this partnership with Nvidia, it’s now faster than ever.

They recently added 504 of Nvidia’s graphics processing units to that same
supercomputer QUADRUPLING its capacity.

George:

Ok, That sounds impressive. But I don’t really have a frame of reference. How
does that compare with the competition?

Marc:

Let me put it this way…

Each year, a list of the 500 most powerful supercomputers in the whole world is
released.

That includes supercomputers used by the DOE, NASA, Microsoft…

And this small company is near the top of that list.

Meanwhile, not a single other pharma or biotech even cracks the top 500. Not
one.

This firm is truly in a league all of its own.

George:

Amazing.

And what do they do with this ultra-fast computer?

Marc:

Its platform can simulate 2.8 quadrillion molecule interactions.

Just to give you an idea of how big that number is, if you were to spread $2.8
quadrillion evenly among every one of the 8 billion people on earth, each of us
would end up with more than $350,000.

This allows the company to identify compounds that can potentially cure disease
at a lightning pace that we have never seen before.

Imagine a company able to take any disease… and use this AI supercomputer to
find the best treatment for it in minutes.

That’s the future that’s coming.

And this company is leading the charge.

In fact, the upcoming announcement is going to make it clear to the world that
this tiny firm could become one of the most valuable stocks in the entire
market.

George:

I have to say, it’s kind of hard to believe that this company isn’t already a
household name.

Why do you think that is?

Marc:

Well, George, it only recently went public. And, again, this company is still
very small.

It’s trading for less than $10 a share!

But I firmly believe that as soon as September 1, all of that will change.

And I’m predicting investors who get position ahead of that could see gains as
high as 550% in the next 6 months on a special trade I’ve identified...

George:

I assume you’re talking about FDA approval of one of these AI-developed
treatments?

Marc:

Actually, no.

Don’t get me wrong, FDA approval is great for share prices.

But what a lot of people don’t realize… is there’s another catalyst that has
historically been known to generate FAR more explosive gains than FDA approval…
and in a MUCH shorter time…

As much as 509% MORE gains in some cases.

George:

Wow. I didn’t think it got any better than FDA approval for biotech stocks.

Marc:

Here are a few of the best examples I could find that might help change your
mind...

Shares of UNITY Biotechnology immediately doubled following this same type of
catalyst.

Ambrx Biopharma skyrocketed over 1,000% in one day.

And… this one is crazy…. Aquinix Pharmaceuticals jumped as high as 2,000% within
a day.

George:

And you think this time, when Nvidia’s favorite biotech makes its historic
announcement… it could be just as big?

Marc:

George, there is more going on this time than this one, huge catalyst.

Once this biotech makes its announcement – outside of resulting in a giant,
quick gain – I believe it is going to set off a chain of events that’s going to
lead to something so much bigger.

And there’s going to be a unique way to play it, which will get into more in a
minute.

The end result could easily be one of the greatest stock success stories of our
lifetime.

George:

Now, Marc, you mentioned this a moment ago...

You’re targeting a 550%-plus on the special trade you’ve lined up... within
about 6 months?

Marc:

That’s right. I’m going to stay conservative here.

I don’t want to go overboard.

Because this could go even higher than my projection.

George:

But that would be enough to turn $2,000 into $11.000... in just six months.

And I should point out that you’ve made predictions like this before... like
when you predicted a 519% gain on AbbVie in a year... that ended up being
conservative as well.

The complete trade landed a whopping 907% in JUST 10 months...

Marc:

Right, well, actually... 907% was the weighted average. We closed out the last
portion of that trade for nearly 2,400%.

So it’s not an exact science.

But the opportunity I’m looking at today is the first one I’ve seen that could
actually be BIGGER than what I saw in AbbVie.

Longer term, there’s no telling how high this could go.

Because this catalyst could very well be the spark that ignites a massive shift
in healthcare, life sciences and pharma as we know it.

George:

We’re already seeing that shift to some degree, though, wouldn’t you say?

I saw a recent Seeking Alpha article that said, “AI isn’t just revolutionizing
biotech; it’s reinventing it.”

Marc:

Oh, that’s absolutely true.

And it’s just getting started.

Steve Jobs predicted, “The biggest innovations of the 21st century will be at
the intersection of biology and technology. A new era is beginning.”

And we are in the early stages of that right now.

Some experts predict that by 2040, generative AI could result in $1 trillion in
value for healthcare.

George:

It’s no wonder Nvidia has already staked its claim.

This looks like one of those rare opportunities for investors to get in early
and be positioned to make big money… on an advancement that can transform the
world.

Marc:

George, what we’re witnessing is more than just biotech 2.0. This transformation
is so significant that scientists have come up with a new word for it – TechBio.

George:

Biotech… TechBio… Forgive me for asking… But what’s the difference?

Marc:

In essence:

Biotech research and development starts with biology –> then incorporates data
and technology.

TechBio takes the opposite approach. It starts with data and technology –> then
focuses on biological applications.

And none of it would be possible without AI.

George:

Marc, I’ve been reading up on this. And the data is really startling…

Traditionally, 90% of drugs fail clinical trials…

The process of discovery and development takes up to 16 years…

And it costs as much as $2 billion to bring a drug to market.

The whole system is totally inefficient. It’s no surprise that medical
treatments are so expensive.

But TechBio aims to change all of that…

Marc:

In a major way…

We’re starting to see how AI can accelerate the whole process of discovery and
testing new compounds. It’s taking a fraction of the time… as much as 15 times
faster.

A study by Carnegie Mellon, suggests AI could ultimately cut costs by as much as
70%.

According to the founder and CEO of Nvidia’s favorite biotech, even if they
failed 8 times out of 10 in clinical development – which, if you ask me, is a
very conservative estimate – he said, “we could price all our medicines at half
the price of everybody else and still win.”

That’s game changing.

And Time magazine declared, “The biotech revolution stands to transform
America’s economy as we know it – and it’s coming faster than we expect...
turbocharged by AI.”

George:

So… because of AI… we are uncovering better treatments… faster… for a fraction
of the cost.

It’s no wonder this technology has the potential to be life changing – and life
saving – for millions of people.

Marc:

I’m telling you, THIS is where AI will have the biggest economic impact. And
where early investors can really make a killing.

But the clock is already ticking for Nvidia’s #1 biotech… Again, you’ll want to
be in position by September 1.

George:

So, real quick, before we get into that announcement we’ve been talking about…

Explain to me – and our audience – how AI is doing that… how it’s transforming
traditional biotech into TechBio…

And, please… for my sake… keep it simple…

Marc:

Well, that should be easy because, believe it or not, it is actually pretty
simple.

Take a look at this… Does this look familiar to you?

George:

I’m no expert, but that’s either computer code... or a scene from The Matrix.

Marc:

You might be right about the Matrix. But you’re definitely right about it being
computer code.

Now, take a look at this...

That’s a snapshot of DNA sequencing.

George:

Would you look at that! They’re practically identical.

Marc:

Amazing, isn’t it?

As you can see, humans and computers are both made up of combinations of data.

It’s all code.

And all the diseases we face are somehow impacted by this code.

That’s why some people are completely immune to certain diseases… while others
are almost guaranteed to face a disease based on their genetics.

What TechBio is doing… is using the massive power of AI to identify what
compounds can fix the code… and therefore diagnose and even cure the disease.

Check out these headlines from some of the most reputable sources on the
planet...

Forbes...

Psychology Today...

The University of Toronto...

Harvard...

MIT...

George:

OK, so we see this shift starting to happen... I, for one, am excited about the
potential.

But I am curious...

Going back to Nvidia’s favorite biotech, why do you believe this small company
holds the key to unlocking the next, biggest phase of this TechBio revolution?

You already said this company owns the fastest supercomputer in biopharma.

But I’m guessing it goes beyond that.

Marc:

Correct, it’s not just speed that sets this company apart… That’s the great
thing.

I’ll just focus here on some of the biggest factors.

For one thing, this TechBio leader is far ahead of the curve and has a
first-mover advantage when it comes to AI.

Even back in 2018 – before everyone and their mother was talking about
artificial intelligence… and before this firm even went public – Fortune ranked
it among the top 100 companies leading the way in AI.

The real beauty of its technology is that the more data it’s provided, the more
the platform improves.

And MarketWatch reports that they have warehouses filled with machines that are
constantly feeding it loads of data.

So with every passing second, the platform gets smarter and better.

It’s currently working with 50-petabytes of proprietary biological and chemical
data covering everything from human and rodent cells to model organisms and even
human patients.

George:

Hang on a second... Did you say “petabyte”?

What is a petabyte?

Marc:

Yes, 50 petabytes.

To give you an idea… ONE petabyte is the equivalent of about 500 billion pages
of standard printed text.

And we’re talking here about that... times 50!

George:

Wow. That is a LOT of data… to put it mildly.

Now, don’t worry, folks, in a minute Marc will reveal everything you need to
know about that pivotal announcement expected as soon as September 1.

And how you can stake your claim for the potential profit windfall stemming from
it. As much as 550% in 6 months is the target.

But first, can you tell us a little bit more about the technology and what makes
it so cutting-edge?

Marc:

Of course.

This company’s platform takes living cells and exposes them to different
substances, like drugs or new molecules.

Then, they use cameras to take tons of pictures over time. This way, they can
see how the cells change and what happens to them.

And this platform doesn't just take pictures – it also uses fancy computer
algorithms to analyze them.

It looks for patterns and clues in the images to understand how the cells are
affected by different substances.

George:

So, why is this important?

Marc:

Well, by understanding how cells react to different things, scientists can
discover new medicines or find better ways to treat diseases.

And by doing it this way, they can discover those things in a fraction of the
time it used to take.

The CEO explains it this way:

"Think of it as, like, Google Street View driving around taking pictures of
everything. We have microscopes taking tens of millions of pictures of cells
every week, and we're using a lot of the same AI algorithms to turn those images
into mathematical representations of biology that we think could unlock some
really exciting secrets."

Literally no one else is doing it like this.

The way they are doing it is truly revolutionary.

George:

It definitely sounds like it!

Marc:

They are getting drugs into testing at 20% of the average cost... and vetting
molecules twice as fast!

George:

With that in mind, why WOULDN’T this be the company that people turn to for
cancer, Alzheimer’s, weight loss... you name it?

Marc:

Now you’re getting it!

The weight loss market alone is worth $90 billion... Cancer treatment is a $220
billion market...

And this company trades for less than $10!

George:

OK, Marc, so I understand why Nvidia is going all-in on this TechBio firm.

To me, it’s a no-brainer.

This company is making huge advancements in AI biotech and seems poised for
great things… and massive returns.

Now, earlier you mentioned how 97% of Nvidia’s portfolio is invested in just two
holdings... this small cap being one of them.

I want to hear more about that investment Nvidia made… and what it means for
this company’s stock.

Marc:

Well, Nvidia now has about a $76 million stake in this company.

That is no small figure. Remember, this is a tiny firm we’re talking about.

And that investment could pay off big for Nvidia.

If they are right about the potential of this company… it could lead to billions
of dollars in the future.

And, George, it’s not just an investment…

This is a full-blown partnership.

The CEO of Nvidia announced that a “new era in drug discovery is here.” And that
thanks to its alliance with this company we’ll be able to “decode biology and
get better medicines faster.”

This tiny TechBio will use its massive 50 petabyte dataset to train AI models on
Nvidia's cloud platform.

And Nvidia is rolling out the red carpet. It’s giving this firm priority access
to their latest hardware to optimize these models.

George:

So Nvidia invested a ton of money… and is giving this company the tools to take
their technology to the next level… which, in turn, will give Nvidia a much
higher return on its investment.

Genius!

I wouldn’t expect any less from Nvidia… There’s a reason it’s the king of AI.

Marc:

This little stock popped as high as 121% in one day on the news of Nvidia’s
initial investment.

But again, that’s nothing compared to what I see ahead… I’m targeting a 550%
gain in just 6 months on a special trade I’ll be issuing.

George:

But, Marc, based on everything you’re telling me... I wouldn’t surprised if it
turned out even better!

Marc:

Well, here’s the best part that I haven’t even mentioned yet…

Nvidia’s favorite biotech isn’t like most AI-enabled drug discovery companies.
In fact, it’s very unique.

It not only has this incredible platform… it’s one of the few also actively
developing its own proprietary drug pipeline.

It has… BY FAR… the most advanced pipeline among its competitors.

George:

This story just gets better and better!

Marc:

It sure does.

This company currently has five clinical trials underway and multiple
preclinical projects in progress.

These span everything from neurology, oncology, and immunology. But where this
company really shines is in the field of rare diseases.

And this field is exploding right now.

In fact, the rare disease drug market is projected to nearly double to $435
billion by 2028.

George:

OK, but if a company just focuses on these rare diseases… doesn’t that limit
their upside? If there’s not a big market for it?

Marc:

Actually treatments for rare diseases can create some of the biggest wins on
Wall Street.

Kala Pharmaceuticals surged 266% in a day after the small biotech announced a
drug candidate for a rare eye disease.

And look at AstraZeneca.

It brought in $7.1 billion in a single year on rare disease drug sales.

Nvidia’s favorite biotech is perfectly positioned to go even bigger than
AstraZeneca.

Because its technology has the power to design, develop and treat dozens upon
dozens of rare diseases at a pace that’s truly unprecedented.

In fact, the first rare disease treatment is already underway.

There’s one particular trial coming up very soon that I’m most excited about…

It’s for a brain condition called cerebral cavernous malformation – or CCM.

George:

I can’t say I’ve ever heard of that one.

What is CCM and just how rare is that disease?

Marc:

I won’t give you a biology lesson. But real quick, CCM can cause seizures,
stroke-like symptoms, memory issues, bad headaches, and more. There is no cure
other than brain surgery.

And while it’s true that it is considered a rare disease, it’s more common than
you probably think…

CCM is six times more prevalent than cystic fibrosis, which is estimated to be a
$12 billion market.

George:

And as you said, there’s no competition since there’s really no other treatment…
So this could be really, really big for a company with a market cap around $2
billion.

Marc:

Right…

I mean, Merck is a pharma giant, for example. And shares recently hit a record
high... all thanks to its drug for a super rare lung disease.

But here’s the thing…

This is MUCH bigger than just one rare disease.

Essentially, this will be an announcement to the world.

A changing of the guard.

This will be the moment that people understand the power of the technology this
company has built.

It will be the first drug EVER brought to clinical trial found by machine
learning…

And as soon as September 1, Nvidia’s favorite biotech will announce the result
of their Phase 2 trial.

Once these results hit the market… the world will understand that this company’s
tech is ready NOW to change everything.

This will lead to one blockbuster treatment after another.

And the stock is set to skyrocket as a result.

That’s why it is so crucial investors move in now. Because the announcement
could come at any moment from September 1 on.

George:

There it is! September 1.

Did you hear that, folks?

As early as September 1, this company could be making major headlines when the
first EVER drug from machine learning releases its Phase 2 results.

OK, but Marc, there’s no guarantee the announcement will be positive…

Marc:

No, of course not. There are never any guarantees with this stuff. But consider
this…

Everything leading up to this Phase 2 announcement looks extremely positive.

We’ve already seen that the preclinical data and Phase 1 results were very
positive on this drug.

In the animal study, they found that just adding the compound to drinking water
“significantly” decreased brain lesions.

Not only that, but the drug was extremely well-tolerated in the Phase 1 study.
There wasn’t a single severe side effect.

Now, Phase 2 is when scientists basically want to see if the drug works and
really assess just how safe it is.

And out of the 62 patients enrolled in this trial, the “vast majority” have
elected to continue into the long-term extension study.

I don’t know about you, but I can only think of one reason why they’d want to
continue.

For me, these are huge clues as to what we could expect once the announcement
comes out.

George:

And if anyone understands how this works, it’s you…

Marc:

Well, that Celldex Therapeutics play you mentioned earlier that I had
recommended? It was a 419% stock gain in under a year.

We got in just days ahead of a positive Phase 2 announcement, which actually is
the most important moment for any new treatment.

George:

You said it earlier...It’s even more important than FDA approval.

Marc:

Yes, I’ve found that Phase 2 results tend to have the biggest impact on the
stock… because its these results that give us the best idea how a treatment
works.

Let me give you a few of the best examples.

Ambrx Biopharma.

It released Phase 2 results on its treatment for a breast cancer drug.

The stocks launched over 1,000% in a single day.

And take a look at what happened to Viking Therapeutics…

That company announced positive results of its Phase 2 study of a weight loss
drug and boom…

A 145% gain within 48 hours following that announcement.

On December 4, EyePoint Pharmaceuticals released Phase 2 study results for its
treatment for macular degeneration. The news was good. And sure enough…

Within a day, it was up 175%. By February 12, the stock had soared 349%.

Again, I just want to reiterate that these are straight stock gains.

George:

But what you are talking about today sounds even bigger than these examples.

Marc:

Well, this goes way beyond just one treatment for a single rare disease.

This will kick off a total AI revolution in healthcare.

This is why I’m telling everyone to get in before September 1.

And it’s the reason a company like Nvidia has made a point of buying up $76
million worth of this company’s stock.

They know what kind of impact these Phase 2 results could have.

George:

And you mentioned you have a special trade lined up to take advantage of this
historic event?

Marc:

That’s right. I’m recommending a very specific way to play Nvidia’s favorite
biotech.

Yes, I expect a huge pop in the stock following the Phase 2 announcement as soon
as September 1. But that’s just the beginning…

Because if this is as big as I think it will be, an option could deliver a gain
10X bigger than the stock itself.

George:

OK, now THAT is something I can fully get behind!

Marc:

I only wish I could go back and trade Celldex this same way.

George:

Marc, be serious. I can’t imagine you have any regrets over a 419% stock return
in under a year.

Marc:

Well, I wouldn’t say I regret it.

BUT it’s fair to say that I’ve learned from my earlier successes… and I’m
applying those lessons to Nvidia’s favorite biotech.

This time, we’ll be positioned in every way possible to squeeze as much profit
out of this opportunity as we possibly can.

George:

Marc, this sounds huge…

Marc:

It is.

Of course, there’s risk when it comes to any type of investing, especially in
volatile new markets like AI. So I always tell people not to invest more than
you can afford losing.

But if the announcement goes the way I think it will, we’ll have our first proof
that this new AI drug platform works.

It won’t be some pie-in-the-sky dream that AI can create drugs faster, cheaper
and easier. The world will see that it can really happen.

George:

But of course, the results could come out and not be as good as you think.

Marc:

Of course, that is 100% possible.

But let me ask YOU a question…

Do you believe that Nvidia would make a bet this big if they didn’t have a
pretty good idea that the technology worked?

Not only that… what do you think Nvidia will do once the results are in? What
would you do?

George:

Oh, that’s easy. I’d double down. Heck, I’d quadruple down.

Marc:

Right? It only makes sense.

Once this data is released, I fully expect Nvidia to go “all in” on this company
as a result.

And I don’t see the money train ending with Nvidia.

Once Wall Street sees where Nvidia is funneling its money, what do you think is
going to happen?

George:

It’s practically inevitable. We’ll see cash pour in from every corner of the
market.

Marc:

Absolutely!

Investors who position themselves now… ahead of this huge cash flood that I see
coming… could easily see a small stake grow into a fortune.

Again, I’m targeting a 550% gain in just 6 months...

George:

So let me recap just to make sure I’ve got this right…

You predict we’ll see a strong pop in the stock following the Phase 2
announcement coming as early as September 1… so just a few days from right now.

Then it will be like a domino effect… triggering an even bigger investment from
Nvidia and beyond once this cutting-edge technology is basically proven.

And you recommend a specific way to get positioned to take advantage of all of
that… not just buying the stock... but also a specific option at a very specific
time?

Marc:

George, you hit the nail on the head.

And again, there is so much more that I can’t get into here because time won’t
allow it…

George:

If you want to quickly touch on some of the highlights, we have a minute for
that...

Marc:

Great. Because there are a few things I should still mention...

Earlier I touched on this company’s partnerships with some major players.

As a result, it’s eligible for milestone payments of up to $3.7 billion from
Roche-Genentech…

... Another $1.5 billion from Bayer…

...And yet another $760 million from Takeda…

AND on top of that, they’re eligible for royalties on future sales from all
three of these partners!

And again, its market cap is still only about $2 billion!

George:

That’s amazing.

Adding all of that up, you can double check my math, but just based on the
milestone payments alone, that’s more than 3X its current market cap?

Marc:

Yes. And again, that doesn’t include any potential royalties.

Oh, something else I wanted to bring up…

I mentioned how this company focuses on rare diseases.

From an investment standpoint, that’s great news. Because first of all, there’s
no real competition.

And secondly, they can earn orphan drug designations. That gives them exclusive
marketing rights for seven years and other financial benefits.

A study in Science Direct showed that these orphan drug announcements result in
a “statistically significant surge in share prices...”

But beyond that great news as an investor… That also makes it a company you can
feel good investing in…

Big Pharma tends to ignore these rare and genetic diseases. Without companies
like Nvidia’s favorite biotech, people who suffer from these kinds of illnesses
wouldn’t have much hope.

On top of that… This TechBio is committed to transparency and data sharing so it
can help save as many lives as possible.

I can’t even tell you how rare that is in this competitive industry.

Their #1 goal is to accelerate scientific progress and drug discovery… which
WILL ultimately save lives.

When all is said and done, I predict that this little-known company will become
a household name...

And could easily beat some the great biotech stocks of the last decade… like
Medivation which gained over 10,000%…

Or Questcor Pharmaceuticals which returned 5,000% over 10 years to investors...

Or Illumina which soared more than 3,900% in 10 years.

And it all starts as soon as September 1.

George:

So, then, what would you say to someone who’s watching this and – like me – just
wants to rush out right now and load up on shares?

Marc:

Congratulations.

I just ask them to please write to me in a year and tell me what a difference
this trade has made in their lives.

George:

Exciting stuff!

And I know you have a unique way to play this situation which I’d like to circle
back momentarily.

But, folks, it gets even better…

I mentioned this in the beginning…

Marc has a proven record of uncovering great companies on the verge of
experiencing these sorts of catalysts…

He calls them trigger events.

And certainly, while Phase 2 announcements are a big one, it’s not the only one.

There are others that can quickly propel a stock to massive gains.

Remember, Marc has been following these events for years.

Marc, would you mind showing us some examples of real-time biotech trades you’ve
made that were the result of trigger events?

Marc:

Here’s one of my best…

NPS Pharmaceuticals was pioneering a new treatment for short-bowel syndrome
called Gattex.

And successful product launches are another big trigger event that can result in
huge gains…

So I issued a trade recommendation.

Just a few months later...

NPS Pharmaceuticals SHOCKED the market.

The sales of Gattex were nearly TWICE as much as Wall Street’s estimates.

Anyone who followed my recommendation saw a 550% gain in about 5 months!

George:

550% in 5 months… That’s impressive!

Alright, Marc, so spill the beans… What else do you look for?

We’ve got Phase 2 announcements… product launches… what else?

Marc:

Here’s a another great one from a while back…

I had discovered a company called Onyx Pharmaceuticals. It was successfully
treating kidney and liver cancers with a new drug.

So I recommended a trade in Onyx.

Sure enough... a big trigger event hit.

The company announced Amgen had made an offer to buy it for $120 per share. The
stock went VERTICAL.

And we closed out a portion of a trade I recommended for 230% in just a couple
months.

That turns $5,000 into $16,500.

George:

Alright… I’m adding buyout offers to the list.

I’m sure there are others, but maybe just walk us through one more example…

Marc:

I’ve got a great one in mind…

Because it really shows how one trigger event can lead to another… which leads
to another… etc.

This time, I recommended a play on Idexx Laboratories…

A couple of weeks later, it was announced that the biotech was joining the S&P
500…

And that was soon followed by an incredible earnings release.

We closed a portion of the position for a 196% winner in less than 2 months… But
I held on because I knew that more good news was coming…

And thank god I did…

Because soon after, the company joined the Nasdaq 100.

We ended up closing that final portion for a 398% winner in about 5 months.

George:

Impressive!

Marc:

But NOW I’m even more excited because with the added impact of AI… the number of
trigger events in the market is soaring.

So I knew the time was right to finetune my strategy to come up with something
bigger and better than before.

Going forward, we’re going to target trigger events like product launches,
buyouts, clinical trial announcements, earnings, milestone payments. And, of
course, a few others… Catalysts that we’ve seen blast stocks higher time and
time again.

George:

Marc, this all sounds great. But I’m going to state the obvious here…

You have a clear advantage over the average person when it comes to this stuff.

You’ve had a front-row seat at the world-famous JP Morgan Healthcare conference,
I mean, how many times?

Marc:

Oh jeez. I’m not sure. At least 10.

George:

That’s a lot.

I know you have a network of top CEOs and VIPs on speed dial.

You have a team of researchers working with you.

And over 25 years of experience doing precisely this.

Marc:

That is all true.

And that’s exactly why I want to share my newest research… to let people know
beforehand when and where I expect the next big trigger event.

The first one I want to give details on is Nvidia’s favorite biotech.

For one thing, that September 1 deadline is right around the corner.

And for another, this could be the one that blows them all out of the water.

So I put everything about that – details on the company as well as the very
specific way I recommend playing it – in a special report called: The #1 TechBio
Stock: How to Make a Fortune on Nvidia’s Favorite Biotech.

George:

I can’t wait to get my hands on that one!

So, tell all of us, how do we do that?

Marc:

I’m launching a brand-new VIP research service called Trigger Event Trader.

Anyone watching now... who accepts this invitation to join as a charter
member... will get a free copy of this report.

I’ve made it super simple.

I do all of the research. I look for stocks that have great products and strong
financials...

Then, I look for a trigger event that will shoot that stock higher.

In other words, I do ALL of the heavy lifting.

Then I’ll email an alert out to members with precise instructions – what price
to buy at, how to protect their gains, how to position themselves, and when to
sell.

All they need to do is check their email and decide if they want in. At most, it
should take about 20 minutes a week acting on my recommendations.

And I’ve got some really exciting ones lined up…

George:

Can you touch on those real quick? Give us a little preview of what’s in store?
Besides Nvidia’s favorite biotech, of course…

Marc:

Of course...

Like I said, there is a LOT going on in this part of the market right now. A
bunch of trigger events just around the corner...

Now, one I mentioned briefly earlier was FDA approval...

Thankfully, because of the Prescription Drug User Fee Act of 1992, we know
specifically what day the FDA will decide on a drug.

We call it the PDUFA date.

And as Forbes confirms, “it’s not uncommon for biotech stocks to jump 200% in
one day when its drug is approved by the FDA.”

George:

As an investor, that seems like an absolute dream come true... to know with
certainty when that trigger event will hit.

Marc:

You’re not kidding.

For example, here’s Sarepta Therapeutics, which nearly doubled in a single day
from $28 to $53, when its drug eteplirsen was approved.

And here’s Somaxon Pharmaceuticals’ PDUFA approval for its drug Silenor.

It soared 134% in one day.

And ITCI jumped from around $12 to $36 in a single day when the FDA approved its
drug for schizophrenia.

Imagine going to bed with $10,000 in your account... and then waking up the next
day with nearly $30,000.

That’s how powerful these events can be.

George:

OK, so obviously, this trigger event can spark big moves in the stock. But I’m
going to push back a little bit here, Marc...

There’s no way to know with certainty ahead of time if the FDA is actually going
to approve a drug.

Marc:

George, NOTHING in the markets is ever guaranteed.

But you can look at clues to stack the odds in your favor. And I know just what
to look for...

I dig into results of earlier studies.

I track the strength of the Phase 1 and 2 results.

I look at all of the available research.

And then, of course, I track Wall Street activity. When it spikes... that’s how
we know a drug is expected to be approved.

It’s hard work. But it’s worth it. Because when these hit, the gains can be
tremendous.

George:

Are there any FDA approvals you are targeting now?

Marc:

Yes.

There is a very exciting biotech that developed a new type of targeted therapy
to treat acute myeloid leukemia – one of the toughest types of leukemia to
treat.

It was the first drug of its kind to be granted FDA breakthrough therapy
designation back in 2022.

George:

And that means...?

Marc:

That means it was fast-tracked because preliminary clinical trials showed it was
dramatically more powerful than existing treatments.

George, those early phase clinical trials were nothing short of jaw-dropping.

About one-third of the patients’ cancers disappeared completely.

And follow-up studies have confirmed that it’s not only effective... but it’s
well tolerated with minimal side effects.

George:

And this is for a cancer that you just said is notoriously difficult to treat.

This one sounds like a slam dunk to me.

Marc:

Well, again, there aren’t any guarantees when it comes to FDA approval. But I
can’t imagine a scenario that this drug doesn’t make it through.

The date has already been set. Not surprisingly, the FDA has granted the drug
priority review.

Which means that anyone who wants to get in on this blockbuster before it takes
off has to move quickly.

I put all the details of this one in my other report Catalyst Kings: 3 Stocks
Set to Soar... FAST.

George:

And everyone watching right now can receive that report free along with The #1
TechBio Stock when you claim a charter membership to Marc’s elite trading
research service – Trigger Event Trader.

Now, I just want to point out, your Catalyst Kings report promises 3 stocks set
to soar.

Can you give us a rundown of the other two?

Marc:

The second one is also a biotech with multiple trigger events lined up for the
second half of the year.

They're submitting an application to the FDA for one of their cancer drugs and
then expect to head into Phase 1 trials.

But in even bigger news, they’ll announce Phase 1/2 results for a drug they’ve
developed to treat liver cancer... and you’ve seen how big that could be.

It’s a really small company. But they’ve been pioneers in AI drug development
for years now.

I discovered them through their previous chairman, who I met at the JP Morgan
Healthcare Conference years ago. I’ve been to his house.

And I’ve also had dinner with the current CEO several times over the years.

George:

Those connections can really pay off!

Marc:

I wouldn’t be as successful as I have been without them. That’s for sure.

George:

And that last company in your report? Is it another biotech?

Marc:

Surprisingly, no.

Due to the nature of these trigger events, I often end up targeting biotechs.
But that’s not exclusively the case.

There’s no reason to pigeonhole ourselves to one industry only.

There are plenty of other companies out there that meet my criteria that are
poised to take off thanks to big catalysts. I’m happy to take profits from other
sectors.

And this next one is a small cap tech company that provides AI solutions to
clients like Netflix, Square, Mercedes-Benz... and others.

Additionally, it’s another one of the five companies Nvidia has directly
invested in!

It’s nowhere near the investment we saw in Nvidia’s favorite biotech...

George:

But still...

AI’s biggest powerhouse must see a heck of a lot of potential in this small cap
to even make that move. I mean, they COULD invest in anything.

Marc:

Precisely.

The little company CRUSHED expectations last quarter.

And its next earnings announcement is due around August 9.

I anticipate the news will be very good... enough to send the stock soaring.

But beyond that – remember these trigger events are often like dominoes – this
company is so small yet so successful, that I predict that once the positive
earnings come out, it could be snapped up in an acquisition.

Which would lead to bigger, faster profits.

George:

And again, you can get all of the details of all 3 of these stocks – the small
cap with the upcoming FDA approval date, the biotech with the CEO Marc has on
speed dial, and the tech company that’s ripe for a takeover – in Marc’s urgent
report Catalyst Kings: 3 Stocks Set to Soar... FAST.

Which Marc will send to your inbox once you accept his invitation today to join
Trigger Event Trader.

Marc, why don’t you share all of the details of this special project you’ve been
working on?

Marc:

Trigger Event Trader is a VIP Research Service where I keep subscribers in the
loop on BIG catalysts about to hit certain stocks.

And when I discover a new trigger event about to deliver major potential
profits...

I’ll send simple instructions directly from my secure server to your inbox.

You’ll get full details on the company’s new products, fundamentals and upcoming
catalysts.

I typically will make both a traditional stock recommendation and an options
play. That way we're positioned to play the short-term catalyst for huge quick
gains but also hang on for the ride as the stock continues to race higher.

Of course, it’s entirely up to you however you want to trade it.

I’ll also alert you when it’s time to get out of the trade. You'll receive a
sell alert that looks like this...

And you’ll receive password-protected access to my real-time model portfolio
tracker, which covers all our open positions.

But just know that I live for this stuff...

I am always tracking multiple upcoming catalysts, whether it’s Phase 2
announcements... PDUFA dates... clinical trial data... acquisitions...
earnings... really ANYTHING that can cause a stock to go vertical.

George:

And as another FREE bonus for those of you watching now, Marc has a third
special report that gets into more detail on some of those catalysts.

It’s called Three Trigger Events to Supercharge Your Portfolio.

Marc, can you give us a preview of what we’ll discover?

Marc:

This report details three powerful trigger events that have been proven to serve
up big, fast gains...

First time dividend initiators... earnings surprises... and acquisitions.

For example on that last one I mentioned… Gateway Industries once jumped a rare
18,000% in a single day on a buyout offer.

That turns $100 into $18,000 in just 24 hours!

That’s how powerful these trigger events can be.

You’ll find out how I spot these catalysts BEFORE they hit a stock so you can
position yourself ahead of them.

Because unless you know beforehand that one of these trigger events is coming,
you’ll miss out on the lion's share of the gains.

This report reveals the key elements that need to be in place before each
catalyst so you can identify prime targets before it’s too late.

These are the same key elements I look for while doing my own research... and
that have worked incredibly well for me.

George:

So, for those of you keeping score, you immediately get three free reports with
4 urgent recommendations... plus all of Marc’s recommendations sent directly to
your inbox.

About how many would you say that is?

Marc:

I’ll send two to three recommendations every month. And EACH of them will have a
trigger event coming.

Then, simply decide whether you want to make the trade... enter it into your
brokerage account...

And watch as catalyst after catalyst gives you the shot to multiply your money.

Remember, I typically recommend two trades – an options play and a straight
stock play.

George:

Well, I know from experience that options can be an incredible tool to increase
your returns on stocks.

But in the wrong hands... inexperienced hands... they can be – well – dangerous.

Marc:

You couldn’t be more right about that.

Which is why I put together my Options Masterclass. It walks you through all the
different types of options and how they work.

I will show you how to use options.

I’ll show you how to lower your risk substantially with many of them.

I’ll explain how to get approved for options trades in your brokerage account.

I’ll even show you ways you can actually make some of the lowest-risk trades
with certain options.

If some of the big winners we talked about today sounded interesting to you,
then you need to get my Options Masterclass first.

Once you join my research service, I want to leave no stone unturned in making
sure you have what you need to be successful.

And I always want you to feel comfortable and at ease with what we are doing.

George:

Marc, that’s why I particularly love this next benefit that I want to talk
about. You’re doing something really unique here and I think it’s great.

Because you don’t just make a recommendation, pat your members on the back and
wish them luck.

They’ll have the opportunity to communicate with you directly and in real-time
about the model portfolio.

Marc:

You have to be talking about the quarterly calls. And yes, I’m really excited
about that aspect of Trigger Event Trader, too.

Every quarter I’ll host a LIVE call with all my members. Of course, I can’t give
any personalized investment advice.

But we’ll discuss all the positions in the model portfolio, any upcoming trigger
events I see on the horizon, conversations I’ve had with CEOs in the biotech
space, my thoughts on the overall markets and I’ll answer any questions
directly.

George:

It’s hard to even put a price tag on that sort of access to you.

So, Marc, considering the entire package you’ve put together here... the free
reports... the Options Masterclass... quarterly live calls... 24-36 different
recommendations... Heck, even just considering the sheer profit potential of the
opportunities we discussed today... I have to ask...

How much IS a subscription?

Marc:

I’m so excited to finally launch Trigger Event Trader. And I’ve seen firsthand
how investing at the right time in the right stock can have a huge impact on
someone’s life.

But of course, there’s a LOT that goes into the service... the research, the
team, the tech, the time.

So we wanted to offer this research at a fair price.

We finally landed at $8,000.

However, seeing as how this is a brand-new service, I wanted to do something
special for our charter members...

George:

OK, but hang on...

Before you even say what that special membership price is that you’re offering
today, I wanted to just mention that even that full price of $8,000 per year is
an outright bargain.

We’ve seen the types of gains these trigger events can result in...

You’re predicting a 550% gain in just six months on Nvidia’s favorite biotech
alone…

So yes, I’d say it's a very fair deal.

Knowing what I know now, I can’t think of a better investment.

Marc:

Well, naturally, I agree.

But regardless, we are not charging $8,000 today.

Instead for everyone who's watching now, I'm giving you an invitation to join
Trigger Event Trader for the charter price of just $1,995... that’s a 75%
discount off our regular price.

George:

Marc, I have a feeling that this is one of those times where we'll look back and
realize that modest fee was nothing compared to the tremendous amount of
potential upside.

Marc:

And to thank everyone watching right now, they can get an additional discount
when they apply the promo code on the screen. But that code is only good until
midnight.

George:

That’s incredible.

Marc:

Yeah, and I haven’t even mentioned...

I fully stand behind my research.

In fact, I’m so confident in it that I guarantee you’ll see at least 12 chances
to capture triple-digit gains per our model portfolio in the next year.

If not, I’ll give you a completely FREE YEAR to any of my VIP trading research
services.

I also back everything with a 365-day 100% credit-back guarantee.

And I’m willing to honor the credit at full price!

So you pay just $1,995 today MINUS your promo code discount. But if you’re
unsatisfied for any reason, you get a $8,000 credit toward the retail price of
any service at The Oxford Club.

Simply call or email at any time.

This makes it a risk-free opportunity to join me on my latest venture – Trigger
Event Trader.

George:

Just to quickly recap…

Act now and you’ll get…

 * 12 months of Trigger Event Trader...
 * Roughly 2-3 recommendations per month.
 * Buy Alerts and Sell Alerts via email (and FREE optional text messaging to let
   you know to check your email)
 * 24/7/365 access to the Trigger Event Trader website and Model Portfolio
 * Instant access to the archive of special reports
 * Regular portfolio updates via email and website
 * LIVE Quarterly Calls
 * Marc’s Options Masterclass

Four immediate BUY NOW opportunities via these special reports:

 * The #1 TechBio Stock: How to Make a Fortune on Nvidia’s Favorite Biotech
 * Catalyst Kings: 3 Stocks Set to Soar... FAST

A complete report breaking down 3 of Marc’s favorite catalysts:

 * Three Trigger Events to Supercharge Your Portfolio

And an iron-clad guarantee to ensure your satisfaction.

Does that about cover it?

Marc:

You nailed it.

George:

All you have to do is click the join now button below.

Don’t worry. Clicking the button doesn't obligate you to anything.

You'll simply be taken to a secure order page where you can review the full
package Marc is offering as well as the pricing details of this generous offer.

But just remember...

Nvidia’s favorite biotech is making its announcement as soon as September 1
which means you need to move quickly.

It’s got the most powerful AI supercomputer in all of biotech... that just
became 4 times more powerful.

It’s got 5 trials in the pipeline.

It’s eligible for as much as $6 billion in milestone payments from its partners…
triple the current market cap of the company.

AND Marc predicts an enormous money flood starting in the next few days.

Remember, Marc projects a 550% gain in 6 months on a special trade he’ll be
recommending.

But a quick warning...This is a small cap, after all, and we can’t have a bunch
of people piling in at the same time. So we may have to close this offer at any
time without notice.

Charter spots are filling up as we speak, so go ahead, click the button below to
get started.

And be sure to apply your promo code. The code is on the screen now and you’ll
see it again once you click through to the next page.

Or call our VIP Trading Services Team at 888.570.9830 or 443.353.4537.

Marc, any final words?

Marc:

George, you did a great job of summarizing everything. Thank you.

I’m excited to share Trigger Event Trader and I’m REALLY excited about all of
the opportunities coming out of this biotech revolution we’re seeing now.

Maybe you missed out on Moderna and Pfizer and all of those other legendary
stock stories in recent years.

And listen, it's not often in life you get a do-over. But that’s the opportunity
in front of you today.

And that's why I hope you'll accept my invitation to join Trigger Event Trader.

Just please know that this is moving at a lightning pace and the time to jump on
this is now.

And I’ll say it once more. I want you to write to me months, years, even a
decade from now to tell us how much this opportunity made a difference for you.

Finally, I just wanted to say a big thank you to everyone who joined us here
today. I hope to see you on the inside!

I look forward to a very profitable year together.

George:

And I think I speak for all of us when I say thank YOU, Marc. I know I can’t
wait to dig into my reports.

If you’re ready for the chance at the kind of money we talked about today and
begin enjoying the freedom that comes along with it, then simply click the
button on the bottom of your screen right now.

Thanks for watching.

May 2024

JOIN NOW

© 2024 The Oxford Club, LLC. The Oxford Club is a financial publisher that does
not act as a personal investment advisor for any specific individual. Nor do we
advocate the purchase or sale of any security or investment for any specific
individual. Markets have inherent risks and there can be no guarantee of future
profits. Likewise, our past performance does not assure the same future results.
All the recommendations communicated to members during the life of this service
may not be reflected in this presentation. The stated returns may also include
option trades. We will send all our members regular communications with
specific, timely strategies and updated recommendations; however, you should not
consider any of the communications by our company and employees to you
personalized investment advice. Note that the proprietary recommendations and
analysis we present to members is for the exclusive use of our membership. May
2024.

 
✕


WAIT!

If you leave now, you won’t be able to get Marc Lichtenfeld’s special report,
“The #1 TechBio Stock: How to Make a Fortune on Nvidia’s Favorite Biotech.”

Nor will you get his second free report, “Catalyst Kings: 3 Stocks Set to
Soar... FAST.”

AND you won’t discover his strategy for spotting these trigger events BEFORE
they hit... and before the potential profits start rolling in.

Resume Video Read Transcript
 
✕


PLEASE ENTER YOUR EMAIL ADDRESS TO RESERVE YOUR SPOT WHILE WE PREPARE YOUR FREE
DOSSIER.